Chimeric NK Receptor for Broad-Spectrum Targeting: Enable T cells to efficiently target and eradicate a broad spectrum of tumors and virus infected cells;

Artificial Endodomain for Enhanced Cytotoxicity: Artificial endodomain transduces and amplifies CNK signaling, activating T cells to overcome the immunosuppressive microenvironment and initiate robust cytotoxic effect on targeted cells;

Allogeneic Cell Therapy: CNK-UT is engineered with TCR, HLA knockout features, with specific TPD (Targeted Protein Degradation) elements to degrade NK ligands, minimizing risks of GvHD and HvG.